Skip to main content
Log in

Autism spectrum disorders

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

An Erratum to this article was published on 19 October 2012

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Prevalence of autism spectrum disorders in 2011.

Change history

  • 19 October 2012

    There were some inaccuracies in the description of the compound STX–209 (arbaclofen; Seaside Therapeutics) in the text and table of the article. The compound is currently under Phase IIb clinical investigation for the treatment of the core symptoms of autism spectrum disorders, and it is formulated as an oral rapid disintegrating tablet. This information has been updated in the online version of the article.

References

  1. Datamonitor. Epidemiology: autism spectrum disorders. increasing recognition drives growth of treatable population. Code: HC00106.001 (February 2011).

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

Related links

FURTHER INFORMATION

Autism Speaks website — 19 March 2012 press release

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nightingale, S. Autism spectrum disorders. Nat Rev Drug Discov 11, 745–746 (2012). https://doi.org/10.1038/nrd3771

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3771

  • Springer Nature Limited

This article is cited by

Navigation